Compare
Perrigo Co PLC vs Organon & Co. vs Royalty Pharma plc vs Zoetis Inc.
| Latest fiscal year | Perrigo Co PLC PRGO | Organon & Co. OGN | Royalty Pharma plc RPRX | Zoetis Inc. ZTS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.25B | $6.22B | $2.38B | $9.47B |
| Revenue growth (YoY) | -2.8% | -2.9% | +5.1% | +2.3% |
| Gross margin | 35.1% | 53.3% | n/a | 71.8% (computed) |
| Operating margin | -26.4% | n/a | 65.6% | n/a |
| Net margin | -33.5% | 3.0% | 32.4% | 28.2% |
| Net income | -$1.43B | $187.00M | $770.95M | $2.67B |
| EPS (Diluted) | -$10.29 | $0.72 | $1.78 | $6.02 |
| Operating cash flow | $238.50M | $700.00M | $2.49B | $2.90B |
| Free cash flow | $145.10M | $538.00M | n/a | $2.28B |
| Cash & equivalents | n/a | $574.00M | $618.70M | n/a |
| Total assets | $8.54B | $12.87B | $19.62B | $15.47B |
| Total liabilities | $5.60B | $12.12B | $9.91B | $12.14B |
| Shareholders' equity | $2.94B | $752.00M | $9.71B | $3.33B |
| Return on year-end equity | -48.6% | 24.9% | 7.9% | 80.2% |
| Shares outstanding | 137.60M | 260.32M | n/a | 424.93M |
Revenue, most recent five fiscal years
| Fiscal year | Perrigo Co PLC | Organon & Co. | Royalty Pharma plc | Zoetis Inc. |
|---|---|---|---|---|
| Latest | $4.25B Ended 2025-12-31 | $6.22B Ended 2025-12-31 | $2.38B Ended 2025-12-31 | $9.47B Ended 2025-12-31 |
| 1 year earlier | $4.37B Ended 2024-12-31 | $6.40B Ended 2024-12-31 | $2.26B Ended 2024-12-31 | $9.26B Ended 2024-12-31 |
| 2 years earlier | $4.66B Ended 2023-12-31 | $6.26B Ended 2023-12-31 | $2.35B Ended 2023-12-31 | $8.54B Ended 2023-12-31 |
| 3 years earlier | $4.45B Ended 2022-12-31 | $6.17B Ended 2022-12-31 | $2.24B Ended 2022-12-31 | $8.08B Ended 2022-12-31 |
| 4 years earlier | $4.14B Ended 2021-12-31 | $6.30B Ended 2021-12-31 | $2.29B Ended 2021-12-31 | $7.78B Ended 2021-12-31 |